Structure-guided identification and functional evaluation of small-molecule candidates predicted to target the LAG-3/MHC-II interface.
Small-molecule modulators may complement antibody therapy, offering potential advantages such as optimizable chemical structures, improved tumor accessibility, and better flexibility in pharmacokinetic control. Lymphocyte activation gene-3 (LAG-3) is an inhibitory immune checkpoint receptor that suppresses T-cell funct...